Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Legend Biotech CorporationNASDAQ: LEGN
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables turns negative
Q3 FY2026 accounts receivables was -$100K, compared with $25.79M a year earlier. Trailing-twelve-month accounts receivables was -$125.44M.
Context
- Accounts receivables amounted to 12.9% of revenue in FY2025, down 2.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$100K or moves back toward the trailing-twelve-month quarterly average of -$31.36M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (132.85M) USD
- Year-over-year change
- -241.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (132.85M) | -241.7% |
| FY2024 | 2024-12-31 | 93.75M | +194.7% |
| FY2023 | 2023-12-31 | (98.98M) | -296.7% |
| FY2022 | 2022-12-31 | 50.32M | +104.6% |
| FY2021 | 2021-12-31 | 24.59M | — |
Accounts Receivables vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's LTM Sep 2026 accounts receivables of $125.44M is the largest of the 11 companies compared; the peer median is $189K.
- Its year-over-year change of +174128.2% is the highest of 8, against a peer median of -56.7%.
- Accounts receivables amounts to 9.2% of revenue for LEGN, versus a peer median of 13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $125.44M | +174128.2% | — | 9.2% | |
| LTM Mar 2026 | $13.46M | -6.1% | — | 14.5% | |
| LTM Mar 2026 | $8.88M | -67.1% | — | 38.4% | |
| LTM Mar 2026 | $5.47M | -147.5% | — | 12.1% | |
| LTM Mar 2026 | $2.24M | -96.4% | -20.9% | 3.3% | |
| LTM Mar 2026 | $1.7M | +279.7% | — | 26.9% | |
| LTM Mar 2026 | $1.5M | -42.4% | — | 84.7% | |
| LTM Mar 2026 | $378K | -56.7% | -57.2% | 3.4% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding LEGN) | $189K | -56.7% | -39.0% | 13.3% | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (297.58M) |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.16M | 34.34M | 47.68M | 68.94M | 0 |
| Change in Working Capital | 161.83M | 181.03M | (71.34M) | 20.04M | (93.35M) |
| Accounts Receivables | 24.59M | 50.32M | (98.98M) | 93.75M | (132.85M) |
| Inventory | 51K | (13.89M) | (12.71M) | (17.21M) | (4.51M) |
| Accounts Payables | 1.81M | 72.45M | (50.2M) | 14.06M | 44.52M |
| Other Working Capital | 135.39M | 72.16M | 90.54M | (70.57M) | (501.32K) |
| Other Non-Cash Items | 12.82M | 10.68M | 130.06M | (98.24M) | 261.57M |
| Operating Cash Flow | (198.47M) | (201.28M) | (393.28M) | (144.03M) | (100.47M) |
| Capital Expenditures | (45.4M) | (22.28M) | (22.72M) | (14.11M) | (67.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (377.96M) | (654.97M) | (4.86B) | (2.71B) | (4.55B) |
| Sales of Investments | 230.08M | 614.86M | 5.08B | 1.93B | 5.33B |
| Other Investing Activities | (4.91M) | (16.05M) | (100.52M) | (54.34M) | 0 |
| Investing Cash Flow | (194.98M) | (77.09M) | 92.79M | (850.54M) | 711.48M |
| Debt Repayment | (1.42M) | (2.6M) | (3.76M) | (4.02M) | 0 |
| Common Stock Issued | 623.44M | 377.64M | 0 | 0 | 3.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.64M | 2.93M | 795.25M | 9.72M | (3.61M) |
| Financing Cash Flow | 626.66M | 377.98M | 791.49M | 5.7M | (300.79K) |
| Effect of Forex Changes | 34K | (2.51M) | 682K | (2.09M) | 4.37M |
| Net Change in Cash | 233.25M | 97.09M | 491.68M | (990.96M) | 615.09M |
| Free Cash Flow | (243.87M) | (223.56M) | (416M) | (158.14M) | (168.04M) |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.